{"id":"oac-clopicogrel","safety":{"commonSideEffects":[{"rate":"5-15%","effect":"Bleeding (major and minor)"},{"rate":"2-5%","effect":"Gastrointestinal bleeding"},{"rate":"0.5-2%","effect":"Intracranial hemorrhage"},{"rate":"5-10%","effect":"Dyspepsia"},{"rate":"5-10%","effect":"Bruising"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination uses an oral anticoagulant (such as warfarin or a DOAC) to inhibit the coagulation cascade, while clopidogrel, a P2Y12 platelet receptor antagonist, prevents platelet aggregation. Together they provide complementary antithrombotic effects—anticoagulation plus antiplatelet activity—reducing risk of both arterial and venous thromboembolism in high-risk patients.","oneSentence":"OAC (oral anticoagulant) combined with clopidogrel provides dual antiplatelet and anticoagulant therapy to prevent thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:35:12.673Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with indication for anticoagulation"},{"name":"Atrial fibrillation with acute coronary syndrome or percutaneous coronary intervention"},{"name":"Venous thromboembolism with concurrent acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT02247128","phase":"PHASE4","title":"Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2014-01","conditions":"Aortic Valve Disease, Myocardial Infarction, Stroke","enrollment":1016}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"OAC + clopicogrel","genericName":"OAC + clopicogrel","companyName":"St. Antonius Hospital","companyId":"st-antonius-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OAC (oral anticoagulant) combined with clopidogrel provides dual antiplatelet and anticoagulant therapy to prevent thrombotic events. Used for Acute coronary syndrome with indication for anticoagulation, Atrial fibrillation with acute coronary syndrome or percutaneous coronary intervention, Venous thromboembolism with concurrent acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}